NYSE:NVS Novartis (NVS) Stock Price, News & Analysis $105.77 +0.90 (+0.86%) (As of 11/29/2024 04:45 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Novartis Stock (NYSE:NVS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Novartis alerts:Sign Up Key Stats Today's Range$104.86▼$105.9750-Day Range$103.06▼$117.1852-Week Range$92.35▼$120.92Volume679,724 shsAverage Volume1.17 million shsMarket Capitalization$216.19 billionP/E Ratio12.28Dividend Yield2.30%Price Target$121.50Consensus RatingReduce Company OverviewNovartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.Read More… Missed Nvidia? Buy Elon Musk’s “Silent Partner” (Ad)In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.So please click here to see the details because a lot of people could get rich. Novartis Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks71st Percentile Overall ScoreNVS MarketRank™: Novartis scored higher than 71% of companies evaluated by MarketBeat, and ranked 386th out of 964 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.9 / 5Analyst RatingReduce Consensus RatingNovartis has received a consensus rating of Reduce. The company's average rating score is 1.89, and is based on no buy ratings, 8 hold ratings, and 1 sell rating.Amount of Analyst CoverageNovartis has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Novartis' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth9.40% Earnings GrowthEarnings for Novartis are expected to grow by 9.40% in the coming year, from $7.66 to $8.38 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novartis is 12.28, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 120.81.Price to Earnings Ratio vs. SectorThe P/E ratio of Novartis is 12.28, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 109.89.Price to Earnings Growth RatioNovartis has a PEG Ratio of 1.52. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioNovartis has a P/B Ratio of 4.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Novartis' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted0.24% of the float of Novartis has been sold short.Short Interest Ratio / Days to CoverNovartis has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Novartis has recently increased by 0.63%, indicating that investor sentiment is decreasing. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldNovartis pays a meaningful dividend of 2.30%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthNovartis does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Novartis is 28.22%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Novartis will have a dividend payout ratio of 29.00% next year. This indicates that Novartis will be able to sustain or increase its dividend.Read more about Novartis' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.24% of the float of Novartis has been sold short.Short Interest Ratio / Days to CoverNovartis has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Novartis has recently increased by 0.63%, indicating that investor sentiment is decreasing. News and Social Media3.4 / 5News Sentiment1.05 News SentimentNovartis has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Novartis this week, compared to 12 articles on an average week.Search InterestOnly 6 people have searched for NVS on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.MarketBeat Follows18 people have added Novartis to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Novartis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.01% of the stock of Novartis is held by insiders.Percentage Held by InstitutionsOnly 13.12% of the stock of Novartis is held by institutions.Read more about Novartis' insider trading history. Receive NVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter. Email Address NVS Stock News HeadlinesNovartis AG (NVS): A Bull Case TheoryNovember 30 at 9:45 PM | msn.comNovartis AG (NYSE:NVS) Given Consensus Recommendation of "Reduce" by BrokeragesNovember 28 at 2:41 AM | americanbankingnews.comVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up to a location just a few miles from here to show you Elon Musk’s next AI product. I promise what happens next will shock you…”December 1, 2024 | Brownstone Research (Ad)Novartis Kisqali Receives EU Approval For HR+/HER2- Early Breast Cancer At High Recurrence RiskNovember 27, 2024 | markets.businessinsider.comNovartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrenceNovember 27, 2024 | globenewswire.comNovartis to present data from mpre than 65 abstracts as ASH, SABCSNovember 25, 2024 | markets.businessinsider.comNovartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCSNovember 25, 2024 | globenewswire.comAre Hedge Funds Banking on Novartis AG (NVS)’s Core Income Growth?November 23, 2024 | insidermonkey.comSee More Headlines NVS Stock Analysis - Frequently Asked Questions How have NVS shares performed this year? Novartis' stock was trading at $100.97 at the beginning of 2024. Since then, NVS shares have increased by 4.8% and is now trading at $105.77. View the best growth stocks for 2024 here. How were Novartis' earnings last quarter? Novartis AG (NYSE:NVS) released its quarterly earnings results on Tuesday, October, 29th. The company reported $2.06 EPS for the quarter, topping analysts' consensus estimates of $1.94 by $0.12. The company had revenue of $12.82 billion for the quarter, compared to analyst estimates of $12.62 billion. Novartis had a net margin of 35.96% and a trailing twelve-month return on equity of 34.80%. Does Novartis have any subsidiaries? Novartis subsidiaries include Gyroscope Therapeutics, Arctos Medical, Cellerys, Cadent Therapeutics, Vedere Bio, Vedere Bio ll, Amblyotech, and others. Who are Novartis' major shareholders? Novartis' top institutional shareholders include Primecap Management Co. CA (0.59%), Loomis Sayles & Co. L P (0.28%), Franklin Resources Inc. (0.21%) and Wellington Management Group LLP (0.20%). How do I buy shares of Novartis? Shares of NVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Novartis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novartis investors own include BlackRock (BLK), Broadcom (AVGO), UnitedHealth Group (UNH), ServiceNow (NOW), Humana (HUM), TotalEnergies (TTE) and American Water Works (AWK). Company Calendar Last Earnings10/29/2024Today11/30/2024Fiscal Year End12/31/2024Next Earnings (Estimated)1/29/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:NVS CUSIPN/A CIK1114448 Webwww.novartis.com Phone(161) 324-1111Fax41-61-324-7826Employees76,057Year Founded1996Price Target and Rating Average Stock Price Target$121.50 High Stock Price Target$130.00 Low Stock Price Target$114.00 Potential Upside/Downside+14.9%Consensus RatingReduce Rating Score (0-4)1.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$8.61 Trailing P/E Ratio12.28 Forward P/E Ratio13.81 P/E Growth1.51Net Income$14.85 billion Net Margins35.96% Pretax Margin26.01% Return on Equity34.80% Return on Assets15.13% Debt Debt-to-Equity Ratio0.55 Current Ratio1.11 Quick Ratio0.90 Sales & Book Value Annual Sales$49.94 billion Price / Sales4.33 Cash Flow$11.20 per share Price / Cash Flow9.44 Book Value$21.25 per share Price / Book4.98Miscellaneous Outstanding Shares2,044,000,000Free Float2,043,796,000Market Cap$216.19 billion OptionableOptionable Beta0.58 Social Links Unlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.Get This Free Report This page (NYSE:NVS) was last updated on 12/1/2024 by MarketBeat.com Staff From Our PartnersThe latest trend in real estateThese vacation homes are often expensive to maintain and vacant 90% of the year. But thanks to co-ownership, t...Pacaso | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredBofA is watching for a market topU.S. tech stocks have soared so high for so long that they're no longer just minting new millionaires... Th...Chaikin Analytics | SponsoredPaypal, Tesla, SpaceX… Elon's next project is bigger than them allIn February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredThis Crisis Could Be Worse Than 2008Underneath the surface, cracks are forming. Cracks that threaten to shatter everything we know. America ...Behind the Markets | SponsoredYou’re invited! See my NEWEST trading strategyThis could easily be the most lucrative new trading strategy of 2025... So you’re not going to want to miss...Monument Traders Alliance | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novartis AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Novartis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NVS Stock Alerts